Atara Biotherapeutics Investor Relations Material

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company develops its product candidates which is designed to harness the body's innate immune system to treat hematologic cancers including multiple myeloma. The company's research focuses on adoptive immunotherapy methodologies and next-generation products that utilize novel chimeric antigen receptors (CAR) technology to target specific antigens associated with a specific disease or condition.